BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Medall Diagnostics expands RT â?? PCR COVID-19 testing capacity

18 August 2020 | News

Medall is now equipped to conduct 6000 COVID-19 tests per day at its lab located at Guindy in Chennai.



Medall Diagnostics, India's leading integrated diagnostic services provider, has announced a five-fold increase of its RT – PCR COVID-19 testing capacity.

With this expansion, Medall diagnostics is now equipped to conduct 6000 COVID-19 tests per day at its 15,000 square feet central reference lab located at Guindy in Chennai.

The facility, with state-of-the-art testing equipment, reinforces Medall's commitment to offer top-of-the-line testing further cementing Medall's position as the leader in the diagnostics space.

Arjun Ananth, CEO, Medall, said, "India is grappling with a steep daily rise of COVID-19 cases. The need of the hour is quick and large-scale testing to control the spread of the pandemic. With a daily RT-PCR capacity of 6000, we are well poised to serve the needs of the government and the private sector during this time. In addition to RT-PCR capabilities, we also offer Antigen and Antibody tests on multiple platforms."

Medall has also partnered with large NGOs to help bring factories back to life and in this exercise has also partnered closely with corporates in restarting their factories and their place of work. Medall launched a package called 'back to work', to create a healthy and safe workplace. Moreover, Medall has also partnered with various Siddha Institutes to evaluate the efficacy of Siddha medicine in treating COVID-19.